Previous studies had demonstrated that IDH1 mutation was associated with favorable clinical outcomes in GBM patients (12, 13), which was further validated in this study by the results that GBM patients with mutant IDH1 had significantly longer OS and PFS than those with wild-type IDH1 in control group (mOS: 26.45 months vs. 14.80 months, HR = 2.85, 95% CI: 1.51 ~ 5.39, P = 0.002; mPFS: 15.10 months vs. 8.80 months, HR = 2.46, 95% CI: 1.31 ~ 4.61, P = 0.005) (Figure 4). Here, IDH1 is linked to glioblastoma.